Vaccinia: all 74 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic CancerRecruitingNCT07006077Phase 2
• IDOV-Immune for Advanced Solid TumorsRecruitingNCT06910657Phase 1
• Evaluation of Patients' Knowledge of Their Vaccination Status and Their Relationship to Vaccination at Melun HospitalRecruitingNCT06616753
• Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerRecruitingNCT06463665Phase 2
• Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)RecruitingNCT05281471Phase 3
• Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell LymphomaRecruitingNCT04887025Phase 1
• Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-LactCompletedNCT05376527Phase 1Results posted
• Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerCompletedNCT02759588Phase 1/2Results posted
• Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib AloneCompletedNCT02562755Phase 3Results posted
• Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)CompletedNCT02179515Phase 1Results posted
• A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy SubjectsCompletedNCT01668537Phase 2Results posted
• A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver CancerCompletedNCT01636284Phase 2Results posted
• Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal CarcinomaCompletedNCT01394939Phase 1/2Results posted
• A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed SorafenibCompletedNCT01387555Phase 2Results posted
• Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal CarcinomaCompletedNCT01380600Phase 1Results posted
• A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular CarcinomaCompletedNCT01171651Phase 2Results posted
• VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVCompletedNCT01158157Phase 3Results posted
• A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsCompletedNCT01144637Phase 3Results posted
• High Dose IMVAMUNE® in Vaccinia-Naive IndividualsCompletedNCT00879762Phase 2Results posted
• A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced SubjectsCompletedNCT00857493Phase 2Results posted
• A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate CancerCompletedNCT00108732Phase 2Results posted
• Evaluation of Healthcare Workers Knowledge Regarding Their Vaccination Status at Melun HospitalCompletedNCT06650722
• Evaluating the Human Immune Response to the JYNNEOS VaccineActive, not recruitingNCT06366672Early Phase 1
• Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 YearsCompletedNCT05976100Phase 1
• Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 YearsCompletedNCT05846243Phase 2/3
• Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 YearsCompletedNCT05762523Phase 1
• Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In ServiceStatus unknownNCT05092568
• Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic MelanomaStatus unknownNCT04849260Phase 1/2
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsTerminatedNCT04725331Phase 1/2
• Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid TumorsStatus unknownNCT04226066Phase 1/2
• The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 YearsStatus unknownNCT04022148
• Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia VirusWithdrawnNCT03110445Phase 1
• JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the CongoCompletedNCT02977715Phase 3
• VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy AdultsCompletedNCT02408913Phase 1
• A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected AdultsCompletedNCT02218125Phase 1
• Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and MesotheliomaCompletedNCT01766739Phase 1
• Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)CompletedNCT01705223Phase 2
• Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck CancerCompletedNCT01584284Phase 1
• Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive AdultsCompletedNCT01571960Phase 1
• A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal CarcinomatosisCompletedNCT01443260Phase 1/2
• Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy AdultsCompletedNCT01418235Phase 1
• Modified Vaccinia Ankara (MVA) Vaccine StudyCompletedNCT01256853Phase 1
• Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric PatientsCompletedNCT01169584Phase 1
• Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)CompletedNCT00928577
• Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid TumorsCompletedNCT00794131Phase 1
• A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic CarcinomaCompletedNCT00629759Phase 1
• Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid TumorsCompletedNCT00625456Phase 1
• Safety Study of Modified Vaccinia Virus to CancerCompletedNCT00574977Phase 1
• Role of Antimicrobial Peptides in Host Defense Against Vaccinia VirusCompletedNCT00407069
• SIGA-246 to Treat SmallpoxWithdrawnNCT00303225Phase 1
• Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia NaiveTerminatedNCT00282581Phase 1
• Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected AdultsCompletedNCT00252148Phase 1
• Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive SubjectsCompletedNCT00189969Phase 1
• Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic MelanomaCompletedNCT00116597Phase 1/2
• Evaluation and Treatment of Eye Complications of Vaccinia VaccinationCompletedNCT00081835Phase 2
• Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in AdultsCompletedNCT00079820Phase 1
• Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against SmallpoxCompletedNCT00053742Phase 1
• APSV in Vaccinia Naive AdultsCompletedNCT00050518Phase 2
• Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOTCompletedNCT00038987Phase 1/2
• Vaccinia Immune Globulin in Treating or Preventing Vaccinal InfectionWithdrawnNCT00006630Phase 1
• A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated VolunteersCompletedNCT00002261Phase 1
• A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the ProstateCompletedNCT00001382Phase 1
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg DoseCompletedNCT00001056Phase 1
• A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination SchedulesCompletedNCT00001043Phase 1
• A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination SchedulesCompletedNCT00001037Phase 1
• A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive IndividualsCompletedNCT00001026Phase 1
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)CompletedNCT00000968Phase 1
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated SchedulesCompletedNCT00000957Phase 1
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.CompletedNCT00000866Not applicable
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)CompletedNCT00000767Phase 1
• A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope VaccinesCompletedNCT00000746Phase 1
• A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency VirusCompletedNCT00000683Phase 1
• A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)CompletedNCT00000631Phase 1
• Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)CompletedNCT00000630Phase 1

← Vaccinia overview